Adjusting to change in healthcare: Learning from translational research

Martine Leroy|30th March 2016

Healthcare is undergoing a transformative change, which presents challenges to all players in the sector. Factors of change include evolving expectations and requirements from populations and governments, and newcomers to the field that are changing both supply and demand. Established healthcare players like pharma need to control and shape their emerging roles.

In this respect, pharma needs to be more pro-active if it is to strengthen and enhance its role. Its efforts to date seem quite timid.

Translational research organisations are healthcare players who are adjusting their strategies in anticipation of change, thus turning challenges into opportunities. What if pharma learned how to adapt faster and more effectively from these organisations?

Head of Insight Martine Leroy explores this ‘what if’ scenario, outlining the ways that pharma could learn from translational research organisations and improve their approach to the changing healthcare landscape.

Translational research organisations are adjusting their strategy

In the UK, the National Health System (NHS) is a major factor of change in that it places engagement and responsibility of the population in their own health and care at the centre of its policy. This is focusing the transformation of the healthcare landscape on cost-effective, positive patient outcomes. Translational research organisations are responding by adjusting their strategies to align with the NHS, to contribute to delivering better patient outcomes, faster.

Traditionally, the role of translational research is to increase the volume of basic scientific discovery that goes into clinical research and hopefully, become real clinical innovation. This is because historically, there is a waste of basic scientific learning that goes into clinical research, because of lack of focus and funding, amongst other factors. 

 

Download the full article by clicking the button below.

Precision paediatrics: Treating patients with CAR-T

Guest Blogger|9th July 2019

Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy for the first patient in Europe, and how the centre of excellence has adapted to make precision medicine a reality

read more

What does it mean to be an agile organisation

Guest Blogger|27th June 2019

We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market.

read more

Battling breast cancer with precision medicine (Part 2)

Natasha Cowan|20th June 2019

Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives his side of the story and explains how industry can help oncologists treat more patients with targeted therapies.

read more